Drug details

Ilumya (tildrakizumab-asmn injection, for subcutaneous use)

type of Interleukin Inhibitors

Ilumya (tildrakizumab-asmn) injection is an interleukin-23 antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• diarrhea,
• fever,
• weight loss,
• chills,
• stomach pain,
• sweating,
• cough,
• increased urination,
• shortness of breath, and
• pain or burning when you urinate,
• skin sores,
• muscle pain,
• coughing up pink or red mucus

The following drugs are related to Ilumya, either as a replacement or used together:

• Wynzora (calcipotriene and betamethasone dipropionate cream)
• Kimyrsa (oritavancin for injeciton)
• Skyrizi (risankizumab-rzaa injection)
• Spevigo (spesolimab-sbzo injection)